Bleakley Financial Group’s Pyxis Oncology PYXS Stock Holding History

Bleakley Financial Group’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,234	Closed	-$20.2K	–	1020
2023 Q4	$20.2K	Hold	11,234	–	–	﹤0.01%	943
2023 Q3	$22.4K	Buy	+11,234	New	+$26K	﹤0.01%	870
2023 Q2	–	Sell	-18,110	Closed	-$72.6K	–	966
2023 Q1	$72.6K	Buy	+18,110	New	+$36.2K	﹤0.01%	868

Other funds holding PYXS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Bleakley Financial Group's PYXS Position: Q1 2024 in Review

Bleakley Financial Group sold out of Pyxis Oncology (PYXS) in Q1 2024, closing a stake of 11,234 shares — an estimated $20.2K sold.

Bleakley Financial Group first reported a position in PYXS in Q1 2023 and held it in 3 quarters. The position peaked at $72.6K in Q1 2023. 72 funds tracked by Wall St. Rank hold PYXS as of Q1 2024.

Bleakley Financial Group reported no remaining Pyxis Oncology position as of Q1 2024 after selling out during the quarter.
Bleakley Financial Group sold 11,234 Pyxis Oncology shares in Q1 2024, an estimated $20.2K.
Bleakley Financial Group first reported a position in Pyxis Oncology in Q1 2023 and held it in 3 quarters.
Bleakley Financial Group's Pyxis Oncology position peaked at $72.6K in Q1 2023.
72 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2024.

Based on Bleakley Financial Group's 13F filing for Q1 2024, filed 8 May 2024.